Clinical Trials Logo

CCND1 Protein Overexpression clinical trials

View clinical trials related to CCND1 Protein Overexpression.

Filter by:
  • None
  • Page 1

NCT ID: NCT03946878 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Start date: August 13, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well venetoclax and acalabrutinib work in treating patients with mantle cell lymphoma that did not respond to previous treatment or has come back. Venetoclax may cause cancer cell death by blocking the mechanism that cancer cells use to stay alive. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and acalabrutinib together may kill more cancer cells in patients with mantle cell lymphoma.